The efficacy and safety of anlotinib treatment for advanced lung cancer

Figures & data

Table 1 Clinicopathologic features among 58 advanced lung cancer patients

Characteristics	Number	Percentage (%)
Gender
Male	43	74.1
Female	15	25.9
Age (years)
Mean	62 years
<60	27	46.6
≥60	31	53.4
ECOG PS
0–1	45	77.6
2	10	17.2
3	3	5.2
Histologic type
Adenocarcinoma	34	58.6
Squamous	16	27.6
Small cell lung cancer	6	10.3
Other	2	3.4
Smoking status
No	16	27.6
Yes	42	72.4
EGFR mutation
Yes	17	29.3
No	41	70.7
Previous EGFR-TKI targeted treatment
Yes	15	25.9
No	43	74.1
Treatment lines of anlotinib
Third line	31	53.4
Further line	27	46.6
Receiving anlotinib dose
12mg	51	87.9
10mg	7	12.1
Previous anti-vascular drug therapy
Yes	33	56.9%
No	25	43.1%
Previous thoracic radiation therapy
Yes	13	22.4%
No	45	77.6%

Abbreviations: ECOG PS: Eastern Cooperative Oncology Group performance status; EGFR: epidermal growth factor receptor; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor.

Table 2 Univariate analysis of PFS

	PFS	95% CI	P-value
Gender			0.674
Male	3.3	1.8–4.8
Female	3.8	1.2–6.4
Age			0.595
<60	2.4	1.8–5.2
≥60	3.5	0.3–4.4
ECOG PS			0.688
0–1	3.5	1.3–5.6
2–3	2.8	1.5–4.0
Smoking history			0.262
Yes	2.8	1.3–4.2
No	3.8	0.1–7.5
Histology			0.694
Adenocarcinoma	3.3	2.0–4.6
Squamous cell	2.8	0.3–5.8
Others	4.7	1.1–8.2
Line of therapy			0.540
Third-line	2.8	1.0–4.5
Further-line	4.0	2.0–6.0
EGFR status			0.873
Mutation	3.5	0.7–4.8
Wild-type	2.8	1.4–5.6
Previous target therapy			0.140
Yes	4.1	3.0–5.1
No	2.4	1.1–3.6
Previous anti-vascular drug therapy			0.811
Yes	3.8	1.6–5.0
No	2.8	1.1–4.5
Previous thoracic radiation therapy
Yes	1.5	0.9–2.1
No	3.8	2.3–5.3	0.276

Abbreviations: ECOG PS: Eastern Cooperative Oncology Group performance status; PFS, progression free survival; EGFR, epidermal growth factor receptor.

Figure 1 Progression-free survival of patients who treated with anlotinib (A) 46 patients received anlotinib treatment, 3.3 months, 95% CI: 1.595-5.071; (B) for patients receiving anlotinib as third line therapy vs. as further line therapy, 2.8 vs. 4.0 months (P=0.540).

Table 3 Main toxicities of anlotinib treatment

Toxicity	Grades 1–2	Grade 3
Hand-foot syndrome	15 (25.9%)	2 (3.4%)
Hypertension	9 (15.5%)	1 (1.7%)
Fatigue	7 (12.1%)	1 (1.7%)
Anorexia	6 (10.3%)	0
Diarrhea	6 (10.3%)	0
Oral mucositis	6 (10.3%)	0
Liver dysfunction	5 (8.6%)	0
TSH elevation	1 (1.7%)	0
Proteinuria	1 (1.7%)	0
Electrocardiographic abnormality	1 (1.7%)	0

Abbreviation: TSH, thyroid stimulating hormone.